Comparative study of mitoxantrone efficacy profile in patients with relapsing—remitting and secondary progressive multiple sclerosis

ABC-transporter gene-polymorphisms are potential pharmacogenetic markers for mitoxantrone response in multiple sclerosis

(2009) S. Cotte et al.   BRAIN

Multiple sclerosis patients—benefit-risk preferences: Serious adverse event risks versus treatment efficacy

(2009) F. Reed Johnson et al.   JOURNAL OF NEUROLOGY

Revision of the risk of secondary leukaemia after mitoxantrone in multiple sclerosis populations is required

(2009) Ana M Pascual et al.   Multiple Sclerosis Journal

Therapy-related acute leukaemia with Mitoxantrone: what is the risk and can we minimise it?

(2009) R Ellis et al.   Multiple Sclerosis Journal

Alemtuzumab vs. Interferon Beta-1a in Early Multiple Sclerosis

(2008)   NEW ENGLAND JOURNAL OF MEDICINE

Mitoxantrone as induction treatment in aggressive relapsing remitting multiple sclerosis: treatment response factors in a 5 year follow-up observational study of 100 consecutive patients

(2007) E. Le Page et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY